CORDIS
EU research results

CORDIS

English EN

Advanced Studies towards Knowledge on Lyssavirus Encephalitis
Pathogenesis Improving Options for Survival

Project information

Grant agreement ID: 602825

Status

Closed project

  • Start date

    1 November 2013

  • End date

    31 October 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 072 356,40

  • EU contribution

    € 2 994 881

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

Objective

The overall aim of ASKLEPIOS is to unravel and increase our understanding of the mechanisms that govern pathogenesis of rabies virus (RABV) infection, in pursuit of the rational identification of novel therapeutic leads for rabies encephalitis. Several studies have been conducted over the past decades attempting to unravel the pathogenesis of this deadly disease, however with limited success. New knowledge on the mechanisms of the RABV life-cycle and interaction with the host is needed to identifying clinically applicable therapeutic leads, in search of rational intervention strategies. The project objectives are to:
1. Identify molecules that inhibit RABV replication
2. Identify molecules that inhibit detrimental host responses to RABV infection:
3. Show whether opening the blood-brain-barrier (BBB) improves treatment efficacy:
4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective.
In pursuit of these objectives ASKLEPIOS will perform in vitro screening of the anti-viral effect of type-I IFNs, MAP kinase inhibitors and siRNAs. Second, the therapeutic potential of inhibiting the pyroptotic pathway and inflammatory response will be investigated by using inhibitors of caspase-1, IL-1β, TNF-α IL-6 and MAP kinases. Third, the capacity of molecules to reach the brain will be first evaluated using an efficient in vitro BBB system and in vivo mouse studies.. The most efficient molecule to open the BBB will be co-administrated with the selected therapeutic molecules in the subsequent stages of the project. The results will be collected and synthesized and tested in mice to identify the most effective approach. The ability to clear infection and recover from rabies will be evaluated for each therapeutic scheme identified

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Address

Dr Molewaterplein 40
3015 Gd Rotterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 706 679

Administrative Contact

Paul Huber (Mr.)

Participants (9)

THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS

United Kingdom

EU Contribution

€ 470 057

VYZKUMNY USTAV VETERINARNIHO LEKARSTVI

Czechia

EU Contribution

€ 482 506

PANSTWOWY INSTYTUT WETERYNARYJNY - PANSTWOWY INSTYTUT BADAWCZY

Poland

EU Contribution

€ 428 299

SZENT ISTVAN UNIVERSITY

Hungary

EU Contribution

€ 175 459,20

AGRARTUDOMANYI KUTATOKOZPONT

Hungary

EU Contribution

€ 239 940

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 59 040

ARTEMIS BIO-SUPPORT B.V.

Netherlands

EU Contribution

€ 347 360

INSTITUT PASTEUR

France

EU Contribution

€ 21 000

ALLATORVOSTUDOMANYI EGYETEM

Hungary

EU Contribution

€ 64 540,80

Project information

Grant agreement ID: 602825

Status

Closed project

  • Start date

    1 November 2013

  • End date

    31 October 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 4 072 356,40

  • EU contribution

    € 2 994 881

Coordinated by:

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands